Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KPTI, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Selinexor (KPT-330) FDA approved Jul 2019 · Xpovio |
Multiple Myeloma | Phase 3 · NCT05028348 | Active not recruiting |
| Mezigdomide | Multiple Myeloma | Phase 1/2 · NCT02343042 | Recruiting |
| Eltanexor (KPT-8602) | Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1/2 · NCT02649790 | Completed |
| Tipiracil | Metastatic Colorectal Cancer | Phase 2 · NCT04854434 | Terminated |
| Enasidenib | Relapsed Refractory Multiple Myeloma | Phase 1/2 · NCT03732703 | Completed |
| Bendamustine | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1/2 · NCT04607772 | Withdrawn |
| Decitabine and Cedazuridine (ASTX727) | Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1/2 · NCT02649790 | Completed |
| Imlunestrant | Low Grade Ovarian Serous Adenocarcinoma | Phase 2 · NCT07832227 | Not yet recruiting |
| FOLFIRI | Non-Small Cell Lung Carcinoma (NSCLC) | Phase 1/2 · NCT04256707 | Completed |
| Padnarsertib (KPT-9274) | Acute Myeloid Leukemia | Phase 1 · NCT04914845 | Completed |
| Methylprednisolone | Refractory Multiple Myeloma | Phase 1 · NCT04519476 | Unknown |
| Niacin ER | Solid Tumors | Phase 1 · NCT02702492 | Terminated |
| Fludarabine | Acute Leukemia of Ambiguous Lineage in Relapse | Phase 1 · NCT04898894 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not KPTI's own candidates): Cisplatin, Elotuzumab, Pomalidomide, Dexamethasone, Rituximab, Ruxolitinib, Bortezomib, Gemcitabine Hydrochloride, Oxaliplatin, Paclitaxel, Pacritinib, Momelotinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KPTI holds $65.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $23.8M/quarter from operations, an estimated runway of 8.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 80 · High
Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial…10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KPTI files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 2,517,362 | 11.10% | 2026-09-30 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 2,013,106 | 8.88% | 2026-09-30 |
| Affinity Asset Advisors, LLC | Institution (13G, 5%+) | 1,573,517 | 6.94% | 2026-09-30 |
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 1,539,147 | 6.79% | 2026-05-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 1,266,084 | 5.58% | 2026-06-30 |
| Richard A. Paulson President and CEO, Director |
Insider | 269,747 | 1.19% | 2026-05-13 |
| Sohanya Roshan Cheng EVP & Chief Commercial Officer |
Insider | 107,940 | 0.48% | 2026-05-13 |
| Stuart Poulton EVP, Chief Development Officer |
Insider | 94,632 | 0.42% | 2026-07-28 |
| Michael Mano EVP, CLO&Secretary |
Insider | 94,398 | 0.42% | 2026-05-13 |
| Lori Macomber EVP, CFO & Treasurer |
Insider | 85,105 | 0.38% | 2026-02-03 |
| Reshma Rangwala EVP & Chief Medical Officer |
Insider | 56,829 | 0.25% | 2026-05-13 |
| Kristin Abate Chief Accounting Officer |
Insider | 18,616 | 0.08% | 2026-10-16 |
Share count 22,681,460 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KPTI and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →